Q4 EPS Estimate for Entrada Therapeutics Boosted by Analyst

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for shares of Entrada Therapeutics in a note issued to investors on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.66) per share for the quarter, up from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.98 per share.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million.

Separately, Oppenheimer boosted their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday.

Entrada Therapeutics Stock Up 3.1 %

Shares of TRDA opened at $19.82 on Friday. The company has a market cap of $741.66 million, a P/E ratio of 12.47 and a beta of -0.26. Entrada Therapeutics has a fifty-two week low of $10.75 and a fifty-two week high of $19.95. The firm’s 50 day moving average price is $16.40 and its 200 day moving average price is $15.70.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC boosted its holdings in Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after purchasing an additional 11,965 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after buying an additional 13,742 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Entrada Therapeutics in the 1st quarter valued at $79,000. Bank of New York Mellon Corp grew its position in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after buying an additional 14,838 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Entrada Therapeutics by 25.3% during the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after acquiring an additional 7,452 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Insider Buying and Selling at Entrada Therapeutics

In other news, COO Nathan J. Dowden sold 1,904 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.07, for a total transaction of $28,693.28. Following the completion of the transaction, the chief operating officer now directly owns 125,996 shares of the company’s stock, valued at approximately $1,898,759.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, COO Nathan J. Dowden sold 1,904 shares of Entrada Therapeutics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.07, for a total transaction of $28,693.28. Following the completion of the sale, the chief operating officer now directly owns 125,996 shares of the company’s stock, valued at approximately $1,898,759.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the transaction, the insider now owns 183,816 shares of the company’s stock, valued at approximately $2,773,783.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,187 shares of company stock valued at $155,947 in the last quarter. Corporate insiders own 7.59% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.